Objective. The aim of this study was to evaluate the potential efficacy of therapy with thymosin ␣ 1 and ulinastatin for patients with sepsis due to carbapenem-resistant bacteria.
Sepsis is defined as the systemic inflammatory response to infection [1] . The inappropriate use of antibiotics and variation in bacterial susceptibility to these drugs complicate the treatment for sepsis. The emergence of bacteria resistant to carbapenems is alarming because carbapenems are almost the last resort against end-stage infection, especially against infection with gram-negative bacteria. Because the antibiotics that currently exist cannot effectively treat infection due to these bacteria, we urgently need to find a new way to enhance the immune response and adjust the inflammatory reaction. Although bacteria play a leading role in sepsis, the direct cause of death for patients with sepsis is not the bacteria themselves but rather the paralysis of the immune sys-tem and the systemic inflammatory response. Our attention was thus drawn to the immunomodulating reagents thymosin ␣1 (T␣ 1 ) and ulinastatin. T␣ 1 is a naturally occurring thymic peptide first described by Goldstein et al. [2] . It is used worldwide for the treatment of certain viral infections, and its effect is thought to be related to its immunomodulating activities, which are centered primarily on the augmentation of T cell function. Ulinastatin is one of the Kunitz-type protease inhibitors found in urine [3] , and it is generally believed that ulinastatin can control a series of proinflammatory mediators and cytokines [4] . In the present study, our objective was to evaluate the potential efficacy of immunologic therapy with T␣1 and ulinastatin for patients with sepsis due to carbapenem-resistant, gram-negative bacteria. The primary end point was 28-day survival rates, specifically, the comparison of the 28-day rates for patients who received therapy with T␣1 and ulinastatin and the rates for patients who received placebo.
PATIENTS AND METHODS
Study design. This prospective, randomized, and placebocontrolled clinical study consisted of 3 phases: screening, treatment, and follow-up. Before patients were recruited into this study, ethical approval for the study was obtained from the local research ethics committee, and informed consent for participation was obtained for all patients (either from the patients themselves or from relatives, if a patient was not able to give informed consent due to severe sepsis) prior to the performance of any study-related procedures. Patients were enrolled and received treatment in the intensive care unit (ICU) after meeting the following 2 criteria: it had to be established that the patient had sepsis, and it had to be confirmed by culture and by antimicrobial susceptibility testing that the patient was infected with carbapenem-resistant bacteria.
Patients were then randomly assigned to receive either carbapenems in combination with T␣1 and ulinastatin (the CTU group) or carbapenems and the placebo (5% dextroglucose and water for injection) (the CP group); randomization was performed by picking a sealed envelope. Randomization, admission, and the start of randomized treatment occurred on the same day. Patients in the CTU group received an intravenous loading dose of carbapenems, 1.0 g 3 times per day for 10 to 12 days; an intravenous dose of ulinastatin, 200,000 U 3 times per day for 3 days; and a subcutaneous dose of T␣ 1 , 1.6 mg, 2 times per day for 3 days. This was followed by followed by a dose of 100,000 U ulinastatin 3 times per day plus 1.6 mg T␣ 1 once per day for 4 successive days. Patients in the CP group received carbapenems and placebo in the same way. In addition, standard ICU protocol was followed, including empirical therapy for probable infection with gram-positive pathogens, maintenance of blood glucose concentrations between 4 and 6 mmol/L, resuscitation and hemodynamic support, organ support, sedation or analgesia as needed, and adequate nutrition [5] . Generally, imipenem was the first choice for empirical therapy, but when a patient suffered from brain dysfunction, meropenem was used instead. In the present study, weaning from support therapy was performed in accordance with weaning protocol [6] . The physician determined the appropriate time for patients to leave the ICU on the basis of physical examination, laboratory results, and organ-specific parameters.
Patient selection. The diagnosis of sepsis was made in accordance with the criteria of the Consensus Conference Committee of the American College of Chest Physicians and the Society of Critical Care Medicine [7] . In the 6-h period prior to initiation of treatment with the study medication, sepsis was defined as systemic inflammatory response syndrome (SIRS) with a documented infection (i.e., a positive culture result). SIRS was diagnosed when 2 or more of the following criteria were satisfied: temperature Ͼ38°C or Ͻ36°C; heart rate Ͼ90 beats/ Figure 1 . Flow chart illustrating study design and patient outcomes through day 28. APACHE, Acute Physiology and Chronic Health Evaluation; GCS, Glasgow Coma Scale; ICU, intensive care unit; MOF, major organ failure.
min; respiratory rateϾ20 breaths/min; and/or white blood cell count Ͼ12,000 cells/mm 3 , Ͻ4,000 cells/mm 3 , or Ͼ10% immature cells. Patients were considered to be infected with carbapenem-resistant bacteria if the following 2 conditions were met: (1) culture of samples of blood or other body fluids, or specimens from suspected sites of infection, was positive for bacteria more than 3 times, and (2) carbapenem resistance was verified, primarily by disk diffusion, and further documented by antimicrobial susceptibility testing. In these tests, carbapenem resistance was indicated by an inhibition zone diameter for carbapenems of 13 mm, in accordance with the standards of the Clinical and Laboratory Standards Institute [8] , and a minimum inhibitory concentration for carbapenems of 16 mg/L, determined by using the Etest method in accordance with the manufacturer's recommendations (AB Biodisk).
Patients were not eligible if they met any of the following criteria: age Ͻ18 or Ͼ80 years; incurable malignancies with documented metastases; long-term treatment with high-dose immunosuppressive drugs or receipt of high dose nonsteroidal anti-inflammatory drugs within the previous 2 days; acute myocardial infarction; or chronic compensated organ dysfunction, such as chronic liver disease, dialysis-dependent renal failure, and/or moderate to severe chronic heart failure. Initially, there were 60 patients enrolled in each study group. However, 1 patient in the CTU group appeared to experience a gastrointestinal adverse effect after imipenem therapy and could not continue to accept treatment. In the CP group, 1 patient was excluded because of a treatment mistake. In addition, 4 CP group patients were discharged because of improvement in their condition, and these patients were withdrawn from the study. Ultimately, there were 59 subjects in the CTU arm and 55 subjects in the CP arm ( figure 1) .
Patient evaluation. In the original trial design, patients were followed up for a 28-day study period after the first day of treatment or until death, whichever occurred first. To evaluate the long-term effectiveness of therapy with T␣ 1 and ulinastatin, we prolonged follow-up time to 60 and 90 days after the first day of treatment or until death, whichever occurred first, to estimate survival rate and all-cause mortality. The patient's history was recorded and a physical evaluation was performed. Samples of blood and other body fluids and specimens from suspected sites of infection were obtained for culture. Vital signs were documented, hematologic and biochemical tests carried out, and lymphocyte subsets were enumerated and cytokine levels were Comparison of 28-day cumulative survival rates for the patients who received placebo (CP group) and the patients who received thymosin ␣ 1 and ulinastatin (CTU group). The 51.7% cumulative survival rate of the CTU group was 17.8% greater than the 33.9% cumulative survival rate of the CP group (P ϭ .086, by log-rank test; P ϭ .074, by Mann-Whitney U test). NOTE. There were initially 60 patients in each study group, but 1 patient in the CTU group and 4 patients in the CP group were withdrawn, and 1 patient in the CP group was excluded during the study. See Patients and Methods for details.
a Total is greater than the total number of patients in the group because some patients had multiple underlying diseases. b Total is greater than the total number of patients in the group because some patients had multiple pathogens recovered. measured on admission and on days 3, 8, and 28 after admission. Laboratory values and organ-specific parameters were used to calculate the Acute Physiology and Chronic Health Evaluation (APACHE) II [9] score, Multiple Organ Failure (MOF) score [10] , and Glasgow Coma Scale (GCS) [11] .
Medical resources. Synthetic ulinastatin (batch number H19990132) and T␣ 1 (batch number H20020545) were purchased from Techpool Bio-Pharma.
Lymphocyte subset enumeration and cytokine detection. Lymphocyte subsets were counted by use of a flow cytometer (EasyCyte; Guava Technologies). Cytokine levels were determined by ELISA (Genzyme). The detection limits of tumor necrosis factor (TNF)-␣, interleukin (IL)-1␤, IL-4, IL-6, and IL-10 were 2.3 pg/mL, 0.3 pg/mL, 1.32 pg/mL, 0.96 pg/mL, and 0.99 pg/mL, respectively.
Statistical analysis. The primary analysis was based on the 28-day, 60-day, and 90-day cumulative survival rates for the randomized patients. All numeric data was presented as mean (ϮSD). The Mann-Whitney U test was used to evaluate the differences between the groups over time. The whole-curve differences for APACHE II and MOF scores and immunological indexes were compared by use of the Friedman test and Kendall's W, and lymphocyte subsets were compared by use of 1-way analysis of variance. The Kruskal-Wallis test and the Mann-Whitney U test were used to compare APACHE II and MOF scores and immunological indexes between groups at different time points. The Student's t test was used to compare lymphocyte subsets between groups at different time points. Survival rates over time were estimated by the Kaplan-Meier method; the end of follow-up for patients who did not die was considered a censoring event. The log-rank test was used to evaluate the equality of survival distributions between groups; this test was also used to analyze the duration of mechanical ventilation, duration of dopamine therapy, and the duration of ICU stay (all of these were measured in days). Fisher's test was used to compare adverse events between groups. A 2-sided P value Ͻ .05 was considered significant. Due to the small number of patients in this pilot trial, the statistical power was only adequate for detecting large differences between treatment groups. Statistical analyses were calculated using SPSS software (version 13.0; SPSS).
RESULTS
At screening, the distribution of demographic characteristics, underlying diseases at study entry, and infection with antimicrobial-resistant bacteria were well-balanced across the 2 treatment groups. There was no significant difference between the 2 groups in the incidence or duration of therapy with imipenem or meropenem (table 1) .
Effects of T␣ 1 and ulinastatin in patients with sepsis. The effect of treatment with T␣ 1 and ulinastatin on the survival rate of patients with sepsis due to carbapenem-resistant, gramnegative bacteria was analyzed on an intention-to-treat basis. On day 28, there were 16 surviving patients among the 55 recipients NOTE. P values represent the whole-curve analysis that showed whether there were differences within the whole group. If that was the case, comparisons of changes within the study arms from the time of admission were analyzed further. For the patients who received carbapenems, thymosin ␣ 1 , and ulinastatin (the CTU group), P Ͻ .001 for APACHE II and MOF scores between admission and days 3, 8, and 28; for the GCS value between admission and days 8 and 28, P Ͻ .001. For the patients who received carbapenems and placebo (the CP group), P ϭ .036, .021 and .039 for APACHE II, MOF, and GCS, respectively, between admission and day 28. Differences between groups over time: P ϭ .042 for APACHE II, P ϭ .036 for MOF, and P ϭ .166 for GCS. figure 2 . When follow-up time was prolonged to 60 and 90 days, a significant difference was found in the cumulative survival rates of the CTU and CP groups (60-day cumulative survival rates were 52.6% and 26.7%, respectively [P ϭ .046]; 90-day rates were 47.4% and 20.0%, respectively [P ϭ .033]). APACHE II, MOF, and GCS values during treatment. In the CTU group, large whole-curve differences were found in APACHE II, MOF, and GCS values (P Ͻ .001, P Ͻ .001, and P ϭ .010, respectively); the differences in the CP group values were smaller: P ϭ .040, .027, and .051, respectively. In the CTU group, APACHE II and MOF scores were reduced significantly on days 3, 8, and 28 (P Ͻ .001); similar reduction in the CP group was observed only on day 28 (P ϭ .036 and .021, respectively). The GCS value increased on days 8 and 28 in the CTU group (P Ͻ .001) and on 28 day in the CP group (P ϭ .039). Differences in these values over time were found between the groups (P ϭ .042 for APACHE II score, P ϭ .036 for MOF score, and P ϭ .166 for GCS value). When the CTU and CP groups were compared, there were significant differences in APACHE II, MOF, and GCS values on day 8 (P ϭ .001, .017, and .004, respectively) (table 2).
Rate of lymphocyte subset proliferation during treatment. In comparison with the CP group, more rapid alterations in the CD3 ϩ and CD4 ϩ cell populations were found in the CTU group.
Significant differences were observed between groups with respect to the increase of the CD4 ϩ CD8 ϩ cell population over a 28-day period (P ϭ .041). There were significant differences between the CTU group and CP group with respect to CD4 ϩ CD8 ϩ cell population on days 8 and 28 (P ϭ .012 and .039, respectively) (table 3) . The CD4 ϩ CD8 ϩ cell population in the CP group at day 28 was still lower than that of healthy control subjects (P ϭ .036).
Comparison of the concentration of inflammatory mediators. When the CTU and CP groups were compared, inflammatory mediator levels decreased more quickly in the CTU group. The mean levels of TNF-␣ and IL-6 were reduced significantly on days 8 and 28 in the CTU group (P Ͻ .001), as was the mean level of IL-1␤ (P ϭ .031 and .020, respectively). In the CP group, significant differences were found in the level of TNF-␣ and IL-6 on day 8 (P ϭ .012 and .010, respectively) and day 28 (P ϭ .008 and .06, respectively), but significant differences in the level of IL-1␤ appeared only on day 28 (P ϭ .041). The mean levels of IL-4 and IL-10 were increased significantly on day 8 in the CTU group (P Ͻ .001), but not in the CP group. Significant differences were observed between the 2 groups with respect to the mean levels of TNF-␣, IL-1␤, IL-4, IL-6, and IL-10 over the 28-day treatment period (P ϭ .031, .043, .046, .041, and .031, respectively). There were significant differences between the CTU group and the CP group with respect to the mean levels of TNF-␣, IL-1␤, and IL-6 on days 8 and 28 (for day 8, P ϭ .001, .037, and .018, respectively; for day 28, P ϭ .011, .041, and .021 respectively). Significant differences between the 2 groups with respect to the mean levels of IL-4 and IL-10 were observed only on day 8 (P ϭ .040 and Ͻ.001, respectively). Compared with healthy control subjects, mean levels of IL-4, IL-6, and ILϪ10 in the CTU group were higher at day 28; when healthy control subjects were compared to the CP group, mean levels of TNF-␣, IL-1␤, IL-4, IL-6, and IL-10 were higher at day 28 (table 4) . ICU treatment after randomization. During the study, the mean duration of mechanical ventilation, dopamine use, and ICU stay in the CTU group were significantly shorter, compared with the same durations in the CP group (P Ͻ .001). A significant difference in the incidence of shock was found between the 2 groups (P ϭ .026). There were 2 adverse events among patients in the CP group (rash and asthma) and none among patients in the CTU group (table 5) .
DISCUSSION
In the United States, sepsis has the highest mortality rate of any major disease [12] . The present study was focused on patients with sepsis due to carbapenem-resistant bacteria. Resistance to P values represent the whole-curve analysis that showed whether there were differences within the whole group. If that was the case, comparisons of changes within the study arms from the time of admission were analyzed further. For the patients who received carbapenems, thymosin ␣ 1 , and ulinastatin (the CTU group), when admission levels of TNF-␣ and IL-6 were compared with levels on day 8 and day 28, P Ͻ .001 for both comparisons; for IL-1␤, P ϭ .031 and .020, respectively. For the patients who received carbapenems and placebo (the CP group), when the admission and day-8 levels of TNF-␣ and IL-6 were compared, P ϭ .012 and .010, respectively; when admission and day-28 levels were compared, P ϭ .008 and .06, respectively. When the CP group's admission and day-28 levels of IL-1␤ were compared, P ϭ .041. For IL-4 and IL-10, when admission and day-8 levels were compared for the CTU group, P Ͻ .001. P values for differences between the groups over time were as follows: P ϭ .031 for TNF-␣, P ϭ .043 for IL-1␤, P ϭ .046 for IL-4, P ϭ .041 for IL-6, and P ϭ .031 for IL-10. Compared with healthy control subjects, levels of IL-4, IL-6, and IL-10 in the CTU group were higher at day 28 (P ϭ .041, .021, and .018). Levels of TNF-␣, IL-1␤, IL-4, IL-6, and IL-10 in the CP group were higher at day 28 (P ϭ .008, .045, .047, .014, and .010), compared with healthy subjects. carbapenems is likely to result from bacterial production of carbapenemase or ␤-lactamases, as well as loss of major porin, which is predicted to increase resistance to hydrophilic antibiotics. Carbapenems were ineffective for treating the study patients.
In our study, on admission in ICU, the total number of CD3 ϩ , CD4 ϩ , and CD4 ϩ CD8 ϩ cells in patients with sepsis was reduced significantly compared with that in healthy control subjects, suggesting that patients were in an immunosuppressed state characterized by a decrease in both the number and functional capacity of circulating lymphocytes. Fortunately, the percentages of different lymphocytes were all increased after treatment with T␣ 1 and ulinastatin. There was a significant difference between the 2 groups with respect to the size of the CD4 ϩ CD8 ϩ cell population after therapy, with the result of comparative immune function melioration in the CTU group. It is thought that T␣ 1 plays a vital role in this process by inducing T cell and dendritic cell maturation [13] . In sepsis, the proinflammatory response involves the release of TNF-␣, IL-1␤, IL-6, and IL-8 [14] . Anti-inflammatory cytokines such as IL-4, IL-10, and IL-13 are also produced concurrently [15] . In the present study, the levels of TNF-␣, IL-1␤, and IL-6 in the CP group were higher than those in the CTU group after therapy. In contrast, the CP group's levels of IL-4 and IL-10 were lower than levels in the CTU group. A previous study has shown that ulinastatin suppresses the production of TNF-␣, IL-6, and IL-8 [3] , and it accelerates the balance between inflammatory injury and anti-inflammatory protection. In the present study, it was also observed that the TNF-␣ and IL-6 levels of the CTU group dropped faster than those of the CP group, as did IL-1␤ levels, but IL-10 levels increased faster. In some studies on sepsis, IL-6 levels have been consistently higher than TNF-␣ levels. This was not the case in our study. In our opinion, this result could be related to the special characteristics of carbapenemresistant, gram-negative bacteria that initiate different signal transduction as a result of different levels of TNF-␣ and IL-6.
The patients who received therapy with T␣ 1 and ulinastatin demonstrated better performance of individual organ systems, as was shown in overall organ failure scores such as APACHE II and MOF. The beneficial effect of this therapy was further evidenced by the CTU group's shorter duration of mechanical ventilation, shorter duration of dopamine therapy, and shorter ICU stay. The therapy's potentially life-saving effect was also demonstrated by the decreased incidence of shock among the CTU group (20%; P ϭ .026). In a previous report, Lin et al. found that the 28-day mortality rate of patients with multiple organ dysfunction syndrome who were treated with T␣ 1 and ulinastatin decreased from 38.32% to 25.14% (P ϭ .0088), compared with the control group [16] . In the present study, the cumulative survival rate for patients with sepsis due to carbapenem-resistant bacteria who received treatment with T␣ 1 and ulinastatin was 17.8% greater than the 28-day survival rate for the CP group (P ϭ .086).
The importance of day 8 was reflected in our findings regarding lymphocyte subset proliferation and inflammatory mediator levels. When the CP and CTU groups were compared on day 8, the size of the CD4 ϩ CD8 ϩ cell population was greater and levels of IL-4 and IL-10 were higher in the CTU group; the levels of TNF-␣, IL-1␤, and IL-6 were lower. It was noticed that most deaths in the CP group occurred before day 8, whereas the number of deaths in the CTU group during the same period was too small for statistical analysis. This may represent a difference in survival rate that is attributable to the effect of treatment on inflammatory mediators and leukocytes. It is worth noticing that in the CP group, the size of the CD4 ϩ CD8 ϩ cell population and the level of most of inflammatory mediators were not approaching normal values at day 28. Compared with healthy control subjects, the CP group had a smaller CD4 ϩ CD8 ϩ cell population and higher levels of TNF-␣, IL-1␤, and IL-6, suggesting immune paralysis and an unbalanced inflammatory response, accompanied by the antiinflammatory response enhancement evidenced by higher levels of IL-4 and IL-10. When the CTU group at day 28 was compared with healthy control subjects, only IL-4, IL-6, and IL-10 levels were higher in the CTU group. We think this result is related to infection with carbapenem-resistant bacteria with powerful pathogenicity, leading to immune inhibition and imbalance in the inflammatory response to some extent. T␣ 1 and ulinastatin can only enhance the immune response and adjust the inflammatory reaction, however-they cannot directly kill bacteria. Bacterial remnants and other traces of bacteria may be the reason that the CTU group had a somewhat smaller CD4 ϩ CD8 ϩ cell population and higher cytokine levels, compared with control subjects. The immunomodulatory therapy described in this study is promising. However, there are some limitations to this study. It is not clear whether the beneficial effects observed in the study were due to T␣ 1 , ulinastatin, or both agents. In addition, more than one drug (imipenem or meropenem) was used in addition to the study drugs. Further, there was a different number of study patients in each group, and each group was relatively small. For this reason, a larger clinical trial should be conducted to validate the conclusions of the present study.
